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(TD50 = 30); insulins (TD50 = 45); antidepressants (TD50 = 67);
bisphosphonates (TD50 = 82); cardiovascular agents (TD50 = 85);
statins (TD50 = 90); oral antidiabetic agents (TD50 = 90); and
glaucoma medications (TD50 = 120). Rates of medication dis-
continuation among patients who had ﬁlled a prescription
for an in-class medication in the prior 180 days were: inhaled
steroids (TD50 = 60); insulins (TD50 = 130); glaucoma medica-
tions (TD50 = 180); antidepressants (TD50 = 187); cardiovascular
agents (TD50 = 240); oral antidiabetic agents (TD50 = 270);
bisphosphonates (TD50 = 272); and statins (TD50 = 308).
CONCLUSIONS: Patients new to therapy faced a far higher
likelihood of medication discontinuation compared to those with
prior in-class medication experience among all the medication
classes studied. Providers and health care systems may want to
re-engineer care to provide more frequent follow-up and educa-
tion to this commonly treated, high-risk group.
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OBJECTIVES: Poor compliance is the primary reason for sub-
optimal clinical beneﬁt, especially in patients with chronic dis-
eases. Fixed-dose combinations (FDC) and unit-of-use packaging
(UUP) are strategies designed to simplify medication regimen and
potentially improve compliance. The aim of our study is to
systematically analyze the effect of FDC and UUP on compliance
and effectiveness in patients with hypertension (HTA), dyslipi-
demia, AIDS, asthma and diabetes type 2 (DMII). METHODS:
Systematic review (SR) of studies that compare medications com-
bined in a single pill or within a UUP with the same free-drug
combinations in HTA, AIDS, asthma and DMII. Bibliographic
databases were searched from inception to February 2008 with
no date limits. Two reviewers scrutinized retrieved references and
full publications sought of potentially relevant studies were iden-
tiﬁed on the basis of title and/or abstract. Additional relevant
studies were identiﬁed from manual searches. Only studies pub-
lished in English or Spanish were included. Quality of studies was
assessed using speciﬁc instruments according to their design.
RESULTS: A total of 11 original studies (HTA 5; DMII 3; AIDS
2; dyslipidemia 1), 1 SR and 1 metaanalysis of varying quality
were included in the SR. Most originals were retrospective
(72%), based on medical claims (72%) and used medication
possession ratio (RPM) as a proxy of compliance (54%). Some
studies also included self-reported compliance (27%) and mea-
sures of persistence (18%). Only 3 studies reported comparative
effectiveness. Follow-up periods ranged from 16 weeks to 1 year.
Overall, results show a tendency for better compliance and less
missed doses in the FDC and UPP groups compared to free-drug
combination groups. Limited data support noninferiority of FDC
and UUP in terms of effectiveness. CONCLUSIONS: FDC and
UUP seem to improve compliance with no major effects on
effectiveness in patients with chronic diseases. However, evidence
is weak and large randomized controlled trials should be carried
out.
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OBJECTIVES: Health-related quality of life data are frequently
collected in clinical trials from different countries and combined
in analyses. This analysis compared AQLQ data across 16 coun-
tries (17 languages) to evaluate suitability to combine data in
subsequent analyses. METHODS: AQLQ data from the Gaining
Optimal Asthma controL (GOAL) study was used for the analy-
ses. Of 3416 patients treated, 1973 had an overall AQLQ score
at baseline, 1850 at week 12 and 1832 at both. The original
language (North American English) was considered the reference
language (RL). Values within 0.5 of the RL were considered
comparable given that 0.5 is considered a clinically meaningful
difference. RESULTS: Number of patients completing each
AQLQ language varied from 27 (Canadian French) to 256 (Man-
darin Chinese). Mean age ranged from 31.7 years (Spain) to 52.9
years (Norway) and percent of males ranged from 30.3% (Brazil)
to 74.4% (Norway). Mean overall AQLQ score [s.d.] at baseline
in the RL was 4.59 [0.94]. Of the 16 languages all but three,
Chile (3.58 [1.05]), Denmark (5.10 [0.82]) and Spain (5.19
[0.93]), reported mean baseline AQLQ overall scores within 0.5
of the RL. Similar ﬁndings were reported for AQLQ domain
scores, with few countries reporting baseline values outside 0.5
of the RL. Mean change from baseline in the overall AQLQ score
in the RL was 0.89 [1.06], with all translations reporting values
within 0.5 of the RL indicating similar results in all languages.
For the AQLQ domains, only the emotional function domain of
the Norwegian, Canadian French and French for France trans-
lations were outside 0.5 of the RL. CONCLUSIONS: The con-
sistency of baseline and change from baseline scores comparing
16 translations with the original language version supports the
validity of translations used in this study and the combining of
data across countries for analyses.
PRS22
ARETHE MEASUREMENT PROPERTIES OFTHE ASTHMA
QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT
ACROSS LANGUAGES?
Juniper E1,Agier L2,Williams AE3, Frith L4, Gul N4
1McMaster University, Hamilton, Ontario, Canada, 2ENSAI Engineering
School, Bruz, France, 3GlaxoSmithKline R&D, Uxbridge, UK,
4GlaxoSmithKline R&D, London, UK
OBJECTIVES: Health-related quality of life data are frequently
collected in clinical studies from a number of countries and
combined for analysis. This study compared AQLQ data across
16 countries (17 languages) to investigate if the measurement
properties of the AQLQ are sufﬁciently consistent to support
combining data in multinational trials. METHODS: The AQLQ
data from the Gaining Optimal Asthma controL (GOAL) study
was used for the analyses. Of 3416 patients treated, 1973 had
an overall AQLQ score at baseline, 1850 at week 12 and 1832
at both. The original language (North American English) was
considered the reference language (RL). Internal consistency,
construct validity and responsiveness were evaluated for each
translation. RESULTS: Number of patients completing each
AQLQ language varied from 27 (Canadian French) to 256 (Man-
darin Chinese) with 81 patients completing the RL. Mean age
ranged from 31.7 years (Spain) to 52.9 years (Norway) and
percent of males ranged from 30.3% (Brazil) to 74.4%
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(Norway). Cronbach’s alpha (baseline overall score) ranged 0.93
to 0.97 (RL 0.94). Correlation with baseline Asthma Control
Questionnaire (ACQ) and with FEV1 were as expected ranging
from -0.76 to -0.58 (RL -0.69) and -0.02 to 0.41 (RL 0.08)
respectively. Similarly, correlations with change from baseline
for ACQ and FEV1 ranged from -0.83 to -0.61 (RL -0.78) and
-0.11 to 0.56 (RL 0.03). The AQLQ showed ability to detect
changes in ACQ over time in all languages except Danish. CON-
CLUSIONS: The ﬁnding that internal consistency, construct
validity and responsiveness were consistent across languages and
similar to the RL provides evidence of the quality of these trans-
lations and supports the combining of data for analyses.
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OBJECTIVES: To appreciate the effectiveness of treatments that
reduce the frequency or severity of chronic obstructive pulmo-
nary disease (COPD) exacerbations, the quality of life gains that
result from this reduction should be adequately included. In the
current study we evaluated the ability of the EQ-5D to reﬂect
the course of a moderate exacerbation. METHODS: The study
was designed as a prospective cohort study in which the change
in EQ-5D scores over a period of 6 weeks was studied. 59 US
patients, 40 year or older visiting the clinic with a moderate
exacerbation were seen 4 times, i.e. during the screening visit and
approximately 8, 14 and 43 days thereafter. Patients completed
the EQ-5D at each visit. ‘Baseline’ EQ-5D was deﬁned as the
lowest of EQ-5D scores at visit 1 and 2, to capture the point at
which the impact of the exacerbation is most severe. Standard-
ized Response Mean (SRM) was calculated as the change divided
by the standard deviation of change. RESULTS: The mean
EQ-5D VAS and utility scores at baseline were 37 (SD 25; range
1–85) and 0.68 (SD: 0.21; range 0.17 to 1.00), respectively.
Estimated improvements in VAS scores at visit 3 and 4 were
11.8 (p = 0.0012) and 13.9 (p < 0.0001), respectively. Estimated
changes in utility scores were 0.1607 (p < 0.0001) and 0.1534
(p < 0.0001), respectively. SRM for EQ-5D utilities was 0.65,
which was comparable with SRMs for symptoms (cough: 0.587,
dyspnea 0.638). Patients with improvement in peak ﬂow above
the median had a larger improvement in utility (p = 0.030) and
VAS (p = 0.012) than patients with improvement below the
median. Based on curve estimation, an exacerbation results in
average loss of 0.00188 QALY, compared to the same period
with no exacerbation and 0.0286 compared to perfect health.
CONCLUSIONS: EQ-5D VAS and utility are responsive to
recovery from a moderate exacerbation, but changes are small.
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OBJECTIVES: To assess the association between the degree of
asthma control and quality of life and to estimate the direct
medical costs associated with asthma in real life practice.
METHODS: An analytical, cross-sectional study. Study units are
primary care users diagnosed of asthma from all over Spain, aged
18 years or older. A multistage cluster sampling has been used for
sample selection: 230 participating primary care physicians. The
Asthma Control Questionnaire (ACQ) was used to measure
asthma control and EQ-5D / EQ-VAS were used to measure
quality of life in asthmatic patients. The Spearman rank correla-
tion coefﬁcient was calculated in order to assess the relationship
between asthma control and quality of life. Information regard-
ing health care resources (hospitalization days, emergency room
visits, primary care visits and absenteeism days) during the 12
months prior to the visit was collected, expressed as 2008 euros
(according to public tariffs available and inﬂation rate).
RESULTS: Overall, 2159 patients have been evaluated, 42.2%
males, mean age 48.5 (95%CI: 47.7–49.2). Of these, 37.4%
(95%CI: 35.3–39.4) were uncontrolled (score > 1,5) according
to ACQ. EuroQol EQ-5D mean score was 0.82 (95%CI: 0.81–
0.83). Spearman rank correlation coefﬁcient between ACQ
and EQ-5D scores was -0.48879 (p-value < 0.0001), and
between ACQ and EQ-VAS scores was -0.54942 (p-value <
0.0001). Hospitalisations over the last year, resulted in a direct
cost of €54.85 per year and patient. In the same way, emergency
room visits €271.17, primary care visits €161.31 and absentee-
ism €322.89. CONCLUSIONS: Better asthma control is associ-
ated with better quality of life in asthmatic patients. Poor asthma
control leads to a higher use of health care resources and there-
fore higher direct medical costs in asthmatic patients.
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OBJECTIVES: In Thailand, health care resource allocation is
increasingly relying on economic analysis though the presenta-
tion of incremental cost per Quality Adjusted Life Year (QALY)
is still arbitrary given a lack of consensus regarding the appro-
priate monetary value per QALY gained upon which to base
resource allocation decisions. Using the societal perspective this
study aims to explore the feasibility of establishing the monetary
value per QALY gained for use in health resource allocation in
Thailand. It also examined, if available, the differences in mon-
etary value per a QALY gained for different disease severities,
and between prevention and curative interventions. METHODS:
Between March and June 2008 a random sampling household
survey was conducted in eight provinces throughout the country
where 1,080 participants aged between 15–65 years were inter-
viewed face-to-face. Each respondent was randomly asked for
the preferences of current health state and one of the following
hypothetical states namely unilateral/bilateral blindness, hemi/
quadric-paralysis, and mild/moderate-allergy using time traded
off (TTO) and visual analogue scale (VAS). The willingness to
pay (WTP) for prevention and treatment of a given scenario were
elicited using the payment card method. RESULTS: The WTP per
QALY ranged from 0.5–2.5 times of the average annual income.
The relationship between the WTP per QALY and the severity of
illness appears to be an inverted ‘U’ shape. The WTP per QALY
were signiﬁcantly higher for treatment than prevention. CON-
CLUSIONS: The participants highly valued the quality of life;
however, the WTP was severely limited by the ability to pay
especially when the program does not allow participants to
gradually pay over a long period of time (paying all within three
months in this case). It seems not possible to obtain a single value
of WPT per QALY which clearly conﬂicts with the expected
utility theory.
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